Ventricular ectopics by visit for patients with ≥16 h of recorded data (intent-to-treat population)
| Ventricular ectopics | FF/VI 100/25 µg OD (N=201) | FF/VI 200/25 µg OD (N=202) | FP 500 µg BD (N=100) |
|---|---|---|---|
| Screening, n | 111 | 116 | 49 |
| Median | 1.0 | 0.0 | 0.0 |
| Patients n (%) with: | |||
| No VEs | 53 (48) | 61 (53) | 25 (51) |
| >50 VEs (any type) | 11 (10) | 18 (16) | 2 (4) |
| >20 VE couplets | 0 | 0 | 0 |
| ≥1 ventricular singlet | 62 (56) | 63 (54) | 23 (47) |
| ≥1 ventricular couplet | 8 (7) | 6 (5) | 3 (6) |
| ≥1 ventricular run | 1 (<1) | 0 | 0 |
| Day 1, n | 104 | 113 | 47 |
| Median | 1.0 | 0.0 | 0.0 |
| Patients n (%) with: | |||
| No VEs | 49 (47) | 58 (51) | 28 (60) |
| >50 VEs (any type) | 10 (10) | 16 (14) | 1 (2) |
| >20 VE couplets | 0 | 0 | 0 |
| ≥1 ventricular singlet | 58 (56) | 59 (52) | 20 (43) |
| ≥1 ventricular couplet | 6 (6) | 7 (6) | 1 (2) |
| ≥1 ventricular run | 1 (<1) | 0 | 0 |
| Week 28, n | 95 | 90 | 39 |
| Median | 1.0 | 1.0 | 1.0 |
| Patients n (%) with: | |||
| No VEs | 31 (33) | 37 (41) | 17 (44) |
| >50 VEs (any type) | 10 (11) | 12 (13) | 3 (8) |
| >20 VE couplets | 0 | 0 | 0 |
| ≥1 ventricular singlet | 64 (67) | 53 (59) | 21 (54) |
| ≥1 ventricular couplet | 4 (4) | 4 (4) | 1 (3) |
| ≥1 ventricular run | 0 | 0 | 0 |
| Week 52, n | 88 | 82 | 37 |
| Median | 1.0 | 1.0 | 0.0 |
| Patients n (%) with: | |||
| No VEs | 33 (38) | 33 (40) | 20 (54) |
| >50 VEs (any type) | 7 (8) | 12 (15) | 1 (3) |
| >20 VE couplets | 0 | 0 | 0 |
| ≥1 ventricular singlet | 55 (63) | 48 (59) | 17 (46) |
| ≥1 ventricular couplet | 5 (6) | 6 (7) | 0 |
| ≥1 ventricular run | 0 | 1 (1) | 0 |
BD, twice daily; FF, fluticasone furoate; FP, fluticasone propionate; OD, once daily; VE, ventricular ectopics; VI, vilanterol.